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The evolution of prostate cancer from an androgen-
dependent state to one that is androgen-indepen-
dent marks its lethal progression. The androgen
receptor (AR) is essential in both, though its function
in androgen-independent cancers is poorly under-
stood. We have defined the direct AR-dependent
target genes in both androgen-dependent and -inde-
pendent cancer cells by generating AR-dependent
gene expression profiles and AR cistromes. In
contrast to what is found in androgen-dependent
cells, AR selectively upregulates M-phase cell-cycle
genes in androgen-independent cells, including
UBE2C, a gene that inactivates the M-phase check-
point. We find that epigenetic marks at the UBE2C
enhancer, notably histone H3K4 methylation and
FoxA1 transcription factor binding, are present in
androgen-independent cells and direct AR-enhancer
binding and UBE2C activation. Thus, the role of AR in
androgen-independent cancer cells is not to direct
the androgen-dependent gene expression program
without androgen, but rather to execute a distinct
program resulting in androgen-independent growth.INTRODUCTION
Androgens, functioning through the androgen receptor (AR), are
essential for the initiation and progression of prostate cancer
(Heinlein and Chang, 2004). Thus, androgen-ablation therapies,
which involve surgical castration or the use of luteinizing
hormone-releasing hormone (LHRH) agonists (or antagonists),
have been the mainstay of treatment for advanced androgen-
dependent prostate cancer (ADPC) for over 40 years. While
such therapies initially lead to disease regression, in general,
advanced prostate cancer ultimately progresses to an
androgen-independent (AIPC) late stage that is refractory to
current therapies (also termed ‘‘castration-resistant prostate
cancer’’) (Debes and Tindall, 2004; Feldman and Feldman,
2001). As AR is expressed in the vast majority of both ADPC
and AIPC (Heinlein and Chang, 2004; Scher and Sawyers,
2005) and decreasing levels of AR protein expression reduces
both ADPC and AIPC growth in model systems (Chen et al.,
2004; Haag et al., 2005; Heinlein and Chang, 2004), it appears
AR signaling pathways play a critical role in both ADPC and
AIPC.
AR is a member of nuclear hormone receptor superfamily that
regulates target gene expression in a ligand-inducible manner
(Mangelsdorf et al., 1995). Two well-characterized AR target
genes in ADPC are prostate specific antigen (PSA) and the
TMPRSS2-ETS fusion genes. Recent studies have demonstratedCell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc. 245
that control of these target genes involves long-range, combina-
torial regulation by AR, DNA-binding collaborating transcription
factors and non-DNA binding co-regulatory factors (Shang
et al., 2002; Wang et al., 2005; Wang et al., 2007). While the role
of AR target genes in regulating cell-cycle progression in ADPC
have yet to be fully defined, it is well understood that decreased
ADPC growth after AR silencing and/or androgen deprivation
primarily involves a block of the G1/S cell-cycle transition through
AR-dependent regulation of cyclin D1, p21 and p27 (Comstock
and Knudsen, 2007). In contrast, how AR regulates cell growth
in AIPC is not known. Addressing this question is of clinical impor-
tance as it may lead to the identification of specific therapeutic
targets for this lethal stage of the disease. By comparing the
program of gene expression directly regulated by AR in a model
of the progression of ADPC to AIPC and gene and protein expres-
sion from actual AIPC cases we find that AR selectively and
directly upregulates a set of M-phase cell-cycle genes to promote
AIPC growth.
RESULTS
M-phase Cell-Cycle Genes Are Upregulated Genes Both
in a Cell Culture Model of AIPC and in Clinical AIPC
Samples
To mimic the properties of clinical prostate cancer progression,
we utilized LNCaP-abl (abl), an androgen-independent derivative
of the androgen-dependent LNCaP prostate cancer cell line that
was generated after long-term androgen deprivation (Culig et al.,
1999). Consistent with its AIPC phenotype abl cells grow
substantially more rapidly than LNCaP cells in hormone-
depleted medium (see Figure S1A available with this article on-
line). While the physiological androgen 5a-dihydrotestosterone
(DHT) significantly increases LNCaP cell proliferation, it has little
effect on abl cell growth (Figure S1A). To identify genes that
might account for the androgen-independent growth of abl
compared with LNCaP, we examined gene expression profiles
of abl cells in the absence of DHT and LNCaP cells in the
absence and presence of DHT treatment for 4 hr (Figure S1B)
using Affymetrix U133 plus 2.0 expression arrays. Gene
Ontology (GO) analysis of upregulated transcripts in abl
compared with LNCaP in the absence of DHT showed that the
top two enriched GO biological processes are ‘‘cell cycle’’ (p =
2.8 3 1019, modified Fisher exact p value, hereinafter) and
‘‘mitotic cell cycle’’ (p = 2.2 3 1017), suggesting that higher
expression of cell-cycle genes, particularly M-phase genes,
may contribute to AIPC growth. Interestingly, GO analysis of up-
regulated transcripts in abl compared with LNCaP cells treated
with DHT for 4 hr also revealed that ‘‘M phase’’ (p = 8.8 3
1022) and ‘‘Cell cycle’’ (p = 1.4 3 1021) as top two enriched
GO biological processes, suggesting that androgen does not
directly increase cell-cycle gene transcription in LNCaP cells to
promote their growth. This result is consistent with a recent study
demonstrating that androgen induces LNCaP growth through
mTOR activation and a post-transcriptional increase in Cyclin
D protein level (Xu et al., 2006). We next investigated whether
cell-cycles genes are also enriched in upregulated genes from
clinical cases of AIPC compared with ADPC cases. This was
accomplished by re-analyzing gene expression profiles of246 Cell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc.AIPC and ADPC from two clinical studies (Figure S1B) (Stan-
brough et al., 2006; Varambally et al., 2005). In agreement with
the cell line results, the most significantly enriched GO biological
processes categories in clinical AIPC upregulated transcripts are
also ‘‘cell cycle’’ (Varambally dataset, p = 4.73 1015, and Stan-
brough dataset, p = 2.73 1023) and ‘‘mitotic cell cycle’’ (Varam-
bally dataset, p = 6.33 1016, and Stanbrough dataset, p = 1.93
1022). These data demonstrate that expression of cell-cycle
regulatory genes, primarily M-phase genes are enriched in
AIPC and may promote AIPC growth.
AR Upregulates M-Phase Cell-Cycle Genes
to Promote AIPC Growth
Given our finding that expression of specific cell-cycle genes are
upregulated in abl compared with LNCaP and the requirement of
AR for growth of both cell lines (Figure 1A), we hypothesized that
AR promotes AIPC proliferation by upregulating specific cell-
cycle genes. We next performed gene expression profiling to
define AR-dependent genes in abl by transfection of a short inter-
fering RNA (siRNA) against AR (siAR) or a control siRNA (siCon-
trol). As referents, we also performed gene expression analysis
in LNCaP cells following AR silencing and in both cell lines over
a time course of DHT stimulation (0, 4 hr, and 16 hr) (Figure 1B)
(Wang et al., 2007). Unsupervised hierarchical clustering of the
expression data clearly distinguished androgen-regulated genes
and AR-regulated genes that reflect ligand-activated and basal
AR activity, respectively (Figure 1B). Therefore, AR-regulated
genes in AIPC are not the same as those regulated by androgen
in ADPC (Figures 1C and S2). As AR silencing decreases abl cell
proliferation (Figure 1A), we next focused on the AR upregulated
genes in abl cells (i.e., siControl/siAR upregulated genes). Inter-
estingly, GO analysis of 345 abl-specific AR upregulated tran-
scripts (q < 0.05) (Figure 1C) revealed that ‘‘cell cycle’’ (52 tran-
scripts, p = 1.4 3 109) and ‘‘mitotic cell cycle’’ (24 transcripts,
p = 8.0 3 109) are the top two over-represented GO biological
processes. Moreover, comparing these AR upregulated cell-
cycle transcripts in abl cells with upregulated transcripts in clin-
ical AIPC showed very significant overlaps (hypergeometric
distribution, for cell-cycle transcripts: 36% (p = 8.85 3 103)
overlap with Varambally dataset and 50.9% (p = 1.05 3 103)
overlap with Stanbrough dataset; for M phase transcripts:
62.5% (p = 1.20 3 105) overlap with Varambally dataset and
91.7% (p = 4.02 3 1010) overlap with Stanbrough dataset)
(Figure 1D). In contrast to enriched ‘‘cell cycle’’ and ‘‘mitotic cell
cycle’’ GO biological processes for abl-specific AR upregulated
transcripts, the most significantly enriched GO biological
processes for 23 LNCaP-specific basal AR upregulated tran-
scripts and 435 LNCaP-specific transcripts upregulated by 4 hr
DHT treatment (Figure 1C) are ‘‘cellular lipid metabolism’’ (p =
7.73 102) and ‘‘positive regulation of cellular process (p = 9.73
105),’’ respectively. In addition, 291 of 345 transcripts abl-
specific AR upregulated transcripts (q < 0.05) have a higher AR
induced gene expression fold change in abl than in LNCaP cells.
GO analysis of these 291 genes also revealed that ‘‘cell cycle’’
(p = 2.6 3 109) and ‘‘mitotic cell cycle’’ (p = 5.2 3 109) as the
top two enriched GO biological processes. Taken together these
data suggest that AR selectively upregulates M-phase cell-cycle
genes to promote AIPC growth.
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Figure 1. AR Silencing in abl Cells Significantly Decreases M-Phase Cell-Cycle Gene Expression
(A) AR silencing decreases both LNCaP and abl cell proliferation. LNCaP cells were cultured regular RPMI 1640 supplemented with 10% fetal bovine serum (FBS).
abl cells were grown in phenol-red free RPMI 1640 supplemented with 10% charcoal/dextran-stripped FBS. Both cell lines were grown in the absence of supple-
mental DHT. Cells were transfected with two independent AR siRNA. The cell proliferation was measured on day 2 and day 4, after siRNA transfection, using the
WST-1 assay (mean (n = 3) ± SE).
(B) Cluster analysis of genes differentially expressed (q < 0.05) by either DHT treatment and/or siAR transfection. Unsupervised hierarchical clustering of genes
(rows) from cells in different conditions (columns) was performed. Brown and blue color represents upregulation and downregulation, respectively.
(C) A Venn diagram showing the basal AR upregulated genes in LNCaP and abl cells and DHT 4 hr upregulated genes in LNCaP cells.
(D) Comparison of abl-specific AR upregulated genes with upregulated genes in two clinical AIPC datasets (Stanbrough et al., 2006; Varambally et al., 2005).Preferential AR Binding to the M-Phase Genes Leads
to Higher Expression in AIPC
To investigate the underlying regulatory mechanism for the differ-
ential pattern of AR-regulated genes in AIPC and ADPC, we
defined the AR cistrome by combining chromatin immunoprecip-
itation (ChIP) with tiled oligonucleotide microarrays across the
entire human genome (ChIP-on-chip) in abl and LNCaP cells.
Briefly, AR ChIP was first performed in abl and LNCaP cells.
The ChIP-enriched DNA was then amplified and hybridized to
Afftymetrix whole human genome tiling array sets. In order toincrease the sensitivity of our approach (Johnson et al., 2008),
we performed the AR ChIP-on-chip in the presence of DHT in
both cell lines. Our strategy is to identify AR binding sites by
ChIP-on-chip in the presence of androgen followed by the valida-
tion of sites of interest by directed ChIP in both the presence and
absence of androgen. Using the MAT algorithm (Johnson et al.,
2006), we identified 8,708 AR binding sites in LNCaP cells and
6,353 AR binding regions in abl cells based on a stringent false
discovery rate (FDR) of 5% (Figure S3). As positive controls, we
found that these included previously reported AR binding regionsCell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc. 247
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Figure 2. AR Directly Regulates Basal and Activated AR Upregulated Genes in LNCaP and abl Cells
(A) Comparison of AR whole genome binding in LNCaP and abl cells. Triplicate AR whole genome ChIP-on-chip was performed in LNCaP and abl cells treated
with DHT for 4 hr. MAT was used to detect AR ChIP-enriched regions. Each dot represents a binding site. Red dots represents differential binding while dark dots
refers to nondifferential binding.
(B) Correlation of AR binding to differential gene expression in LNCaP and abl cells. The graph represents the percentage of genes having AR binding sites with
20 kb of the transcription start sites. The enrichment of AR binding near the TSS of upregulated genes over whole genome background is statistically significant in
both LNCaP and abl cells (Chi-square test, LNCaP (siControl/siAR, p = 1.823 103; DHT 4 hr/vehicle, p = 2.583 1071; DHT 16 hr/vehicle, p = 9.573 1065), abl
(siControl/siAR, p = 6.90 3 108; DHT 4 hr/vehicle, p = 7.91 3 1046; DHT 16 hr/vehicle, p = 2.06 3 1027).at the PSA,KLK2 and TMPRSS2 genes (Figure S4) (Schuur et al.,
1996; Sun et al., 1997; Wang et al., 2007; Yu et al., 1999). We next
compared AR binding in two cell lines using a less stringent statis-
tical cutoff (p < 13 104 or FDR 15%) to avoid missing true differ-
ential binding sites with low binding affinity (MAT score). LNCaP
cells have a greater number of higher affinity AR binding sites
than do abl cells (Figures 2A and S5), which is consistent with a
previous report showing that androgen signaling activity is signif-
icantly decreased in AIPC compared with ADPC (Tomlins et al.,
2007). Correlation of AR binding sites with activated and basal
AR-regulated genes showed a significant enrichment of AR
binding within 20–50 kb of the transcription start sites (TSS) of up-
regulated genes but not of downregulated genes in both ADPC
and AIPC (Figures 2B and S6), suggesting that these upregulated
genes are primarily direct targets of AR action.
Although in general the level AR occupancy at target sites is
greater in LNCaP cells than in abl cells (Figure 3A), we find greater
occupancy of AR binding near abl-specific AR upregulated cell-
cycle genes and M-phase genes in abl cells than in LNCaP cells
(Figure 3A and Table S2). Greater levels of AR binding are corre-
lated with higher expression of target cell-cycle and M-phase
genes in abl (Figure 3B and Table S2). Directed ChIP for the AR
binding sites near the M-phase cell-cycle regulatory genes
CDC20,UBE2C,CDK1, andANAPC10confirmed that these sites
are preferentially occupied in abl as compared with LNCaP in the
presence of DHT and have significant AR occupancy in the248 Cell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc.absence of hormone only in abl and not in LNCaP (Figure 3C).
We examined the mRNA (Figure 3D) and protein (Figure 3E)
expression ofCDC20,UBE2C, andCDK1 in abl and LNCaP cells
in the absence of hormone and following AR silencing. These
results confirmed that these genes are differentially upregulated
and AR-dependent in abl as compared with LNCaP.
Selective Active Epigenetic Marks and Collaborating
Transcription Factors atM-Phase Gene Enhancers Lead
to Increased AR Occupancy at These Sites in AIPC
Among the specific AR regulated M-phase cell-cycle genes in abl
cells, ubiquitin-conjugating enzyme E2C (UBE2C), an anaphase-
promoting complex (APC)-specific ubiquitin-conjugating enzyme,
is of particular interest as the expression of this gene was recently
found to be critical for inactivating the cell-cycle M-phase check-
point (Reddy et al., 2007). Therefore, we further characterized the
two specific UBE2C AR binding sites that are located 32.8 kb
and +41.6 kb away from the TSS of UBE2C gene in abl cells
(FigureS7).While these twoputativeenhancersare withinordown-
stream of other annotated genes,UBE2C is the onlyAR dependent
gene in the region. In order to test whether these two putative
enhancers communicate with the UBE2C promoter, we performed
quantitative chromosome conformation capture assays (3C-
qPCR) (Hagege et al., 2007). Fixed chromatin from LNCaP and
abl cells treated with DHT or vehicle was digested with BglII fol-
lowed by ligation under low DNA concentrations and reverse
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Figure 3. Higher Occupancy of AR Binding Near the M-Phase Cell-Cycle Genes Leads to Higher Expression Levels of These Genes
in abl Cells
(A) Comparison of MAT score of the nearest and the strongest AR binding site within 50 kb of all genes, basal AR upregulated cell-cycle genes and M phase genes
in LNCaP and abl cells. The difference of all genes and M-phase genes between two cell lines is statistically significant (t test on two independent samples,
means ±SE, nearest binding site (all genes, abl/LNCaP = 0.78-fold, p = 2.173 10154, M-phase genes, abl/LNCaP = 1.75-fold, p = 5.853 104), strongest binding
site (all genes, abl/LNCaP = 0.8-fold, p = 2.48 3 10127, M-phase genes, abl/LNCaP = 1.64-fold, p = 6.29 3 103).
(B) Comparison of gene expression index of all genes, basal AR upregulated cell-cycle and M-phase genes in abl cells. Significant difference is observed between
cell-cycle and M-phase gene expression in two cell lines (t test on two independent samples, means ± SE, cell cycle, 1.13-fold, p = 4.51 3 103, M-phase
1.18-fold, p = 2.65 3 103).
(C) ChIP analysis of AR recruitment to various AR binding sites near cell-cycle genes. The PSA enhancer was used as a positive control. ChIP assays were per-
formed with anti-AR antibodies in the presence (+) and absence (-) of DHT. (mean [n = 2) ± SE).
(D) AR silencing specifically decrease high expression of M-phase genes CDC20, UBE2C and CDK1 in abl cells. Seventy-two hours after siRNA transfection into
LNCaP and abl cells in the absence of DHT, total RNA was isolated and amplified by real-time RT-PCR using gene specific primers (mean [n = 3] ± SE).
(E) AR silencing specifically decreases high protein expression levels of CDC20, UBE2C and CDK1 in abl cells. Western blots were performed using the antibodies
indicated ninety-six hours after siRNA transfection into LNCaP and abl cells without DHT.crosslinking. The ligation products were quantified using Taqman
real-time PCR. This revealed significantly greater interaction
between these two putative enhancers and the UBE2C promoter
in abl cells than in LNCaP cells in the absence of hormone
(Figure 4A). In order to determine the mechanism of the preferential
occupancy of the UBE2C enhancer sequences inabl we examined
whether there were abl-specific sequence alterations in these
regions. Sequencingof the twoUBE2Cenhancer regions identified
byAR ChIP-on-chip inLNCaP and abl cells revealed that these two
regions are 100% identical in the two cell lines (data not shown).Given our previous findings that collaborating transcription
factors and coactivators may assist nuclear receptor binding in
certain regions (Carroll et al., 2005; Shao et al., 2004; Wang
et al., 2007), we then investigated whether the previously identi-
fied AR collaborating factors FoxA1, GATA2 and Oct1 (Wang
et al., 2007) and AR coactivator MED1 (TRAP220) (Wang et al.,
2005, 2002) are differentially recruited to the UBE2C enhancers
in two cell lines. Directed ChIP analysis showed significantly
higher occupancy of FoxA1 and MED1 to both enhancers and
GATA2 to enhancer 2 in abl cells as compared with LNCaP cellsCell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc. 249
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Figure 4. Higher Levels of Active Epigenetic Histone Marks and Recruitment of Collaborating Factors Are Correlated with Greater AR Occu-
pancy on the UBE2C Enhancers in abl Cells
(A) Upper panel: Schematic diagram showing the UBE2C locus. The arrows indicate the location and the direction of primers used in the 3C-qPCR assays. The
anchor primer (A) and the Taqman probe were designed in the BglII fragment containing the UBE2C promoter. All other test primers (C1, C2, C3, E1, and E2) were
designed within 50 bp to the restriction sites. Lower panel: The two UBE2C enhancers interact with the UBE2C promoter in abl cells. 3C assays were performed
using BglII enzyme in LNCaP and abl cells in the presence (+) and absence () of DHT (mean [n = 2] ± SE).
(B and C) Stronger FoxA1 and MED1 binding to the UBE2C enhancer 1 and FoxA1, GATA2 and MED1 binding to the UBE2C enhancer 2 in abl cells than in LNCaP
cells. ChIP assays were performed using antibodies against FoxA1, GATA2, Oct1, MED1 and P-pol II ser 5 in LNCaP and abl cells treated with (+) and without ()
androgen (mean [n = 2] ± SE).
(D) Higher p-pol II ser 5 occupancy on the UBE2C promoter in abl cells than in LNCaP cells. P-pol II ser 5 binding at the PSA promoter was served as a control.
ChIP assays were conducted in LNCaP and abl cells in the presence (+) and absence () of DHT using an anti-p-pol II ser 5 antibody (mean [n = 2] ± SE).
(E) Effects of siRNA on UBE2C gene expression in LNCaP and abl cells. Real-time PCR was performed seventy-two hours after siRNA transfection in the absence
of DHT (mean [n = 3] ± SE).
(F) Comparison of protein expression in LNCaP and abl cells by western blots. Western blots analyses were performed comparing AR, PSA, FoxA1, GATA2, Oct1,
MED1, and KDM1 protein expression levels in the absence and presence of DHT (0.1 nM and 100 nM).
(G and H) UBE2C enhancers 1 (G) and 2 (H) have higher H3K4me1 and H3K4me2 levels in abl cells than in LNCaP cells. Levels of H3K4 me1, H3K4me2 and
H3K4me3 on UBE2C enhancers were determined by ChIP assays in the presence (+) and absence (-) of DHT using specific antibodies against H3K4 me1,
H3K4me2 and H3K4me3 (mean [n = 2] ± SE).(Figures 4B and 4C). We also examined serine 5 phosphorylated
polymerase II (P-pol II ser 5) occupancy at the UBE2C promoter
in both cell lines (Figure 4D). We find significantly greater P-pol II
ser 5 occupancy at the UBE2C promoter in abl compared with
LNCaP cells that is unchanged by the addition of DHT. In
contrast, at the PSA promoter P-pol II ser 5 occupancy is signif-250 Cell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc.icantly greater in LNCaP cells and is stimulated by DHT. The
greater level of AR transcription complex loading on the UBE2C
enhancers leads to a greater level of P-pol II ser 5 at the promoter
through chromosomal looping (Figure 4A), resulting in higher
UBE2C expression levels in abl cells (Figures 3D and 4E). Impor-
tantly, silencing of FoxA1, GATA2 or MED1 decreases UBE2C
mRNA level in abl cells but not in LNCaP cells (Figure 4E), sug-
gesting that each of these factors plays an indispensable role
in mediating UBE2C expression.
Interestingly, while minimally greater levels MED1 protein
expression in abl (Figure 4F) might account for greater MED1
recruitment to the UBE2C enhancers, differences in expression
do not account for the differential recruitment of FoxA1 and
GATA2 to the UBE2C enhancers. We have recently defined
a role for the active enhancer histone marks H3 lysine 4 mono-
and di-methyl (H3K4me1 and H3K4me2) (Bernstein et al.,
2005; Heintzman et al., 2007) in specifying sites of FoxA1 recruit-
ment in various cell types (Lupien et al., 2008), we therefore
examined the levels of these marks (and as control the
promoter-specific H3K4me3 mark) at the UBE2C enhancers.
We find that H3K4me1 and H3K4me2 are significantly enriched
at the UBE2C enhancers only in abl and not in LNCaP (Figures
4G and 4H) suggesting that these epigenetic marks may define
these sites as abl-specific enhancers leading to AR-dependent
expression of UBE2C only in this cell type.
In order to determine whether H3K4 methylation is required for
the increased AR occupancy at the UBE2C enhancers in abl
cells we overexpressed a H3K4me1 and H3K4me2 specific de-
methylase KDM1 (Shi et al., 2004) in both LNCaP and abl cells.
Consistent with our recent finding that KDM1 overexpression
reduces FoxA1 recruitment in MCF7 cells (Lupien et al., 2008),
we found that KDM1 overexpression decreases FoxA1 binding
and H3K4me2 level at the UBE2C enhancers (Figure S8). More
significantly, overexpression of KDM1 almost completely abol-
ishes AR binding in both cell lines (Figure 5A), suggesting that
H3K4 marks are required for differential AR binding at the
UBE2C enhancers in LNCaP and abl cells. Interestingly, FoxA1
silencing also almost fully abolishes AR binding at the UBE2C
enhancers in LNCaP and abl cells (Figure 5B), suggesting
FoxA1 binding is also essential for differential AR recruitment.
By contrast, silencing of AR has no effect on differential
H3K4me2 level and FoxA1 binding on the UBE2C enhancers
(Figure 5C). In addition, FoxA1 silencing has no effect on differ-
ential H3K4me2 levels on the UBE2C enhancers (Figure S9).
Thus the differential H3K4 marks and FoxA1 act upstream of
AR and are required for differential AR binding at the UBE2C
enhancers (Figure 5D).
To confirm that the requirement for H3K4 methylation and
FoxA1 binding for AR binding was not restricted to the UBE2C
enhancers, we performed H3K4me1, H3K4me2 and FoxA1
ChIP on the CDK1, CDC20 and ANAPC10 enhancers. We find
that the levels of H3K4 methyl marks and FoxA1 are also higher
on these enhancers in abl cells than LNCaP cells (Figure S10). As
controls, the H3K4 marks and FoxA1 are not present at randomly
selected androgen responsive elements (ARE) that have no AR
binding (Figure S10). As expected, overexpression of KDM1 or
silencing of FoxA1 also significantly decreases AR binding on
the CDK1 and CDC20 enhancers (Figure S11). Moreover, over-
expression of UBE2C does not increase AR binding at the
CDK1, CDC20 and ANAPC10 enhancers in LNCaP cells
(Figure S12). These findings suggest that increased AR binding
at the enhancers of other M-phase genes in abl cells is also
determined by H3K4 methylation and FoxA1 binding rather
than being the result of increased UBE2C expression.Higher Levels of H3K4 Methylation and FoxA1 Binding
at the UBE2C Enhancers Leads to Overexpression
of UBE2C Protein in AIPC Cases
In order to confirm that AR-dependent overexpression of UBE2C
is not unique to abl cells, we determined UBE2C protein expres-
sion levels in another model of AIPC and in clinical AIPC cases.
We confirmed that UBE2C protein level is greater and AR-
dependent in the androgen-independent cell line C4-2B (Thal-
mann et al., 2000) than in LNCaP (Figure S13). More significantly
we examined UBE2C protein expression in clinical cases of
AIPC. We measured by immunohistochemistry UBE2C protein
levels in tissue microarrays containing normal prostate, ADPC
and AIPC tissues (n = 372 tissue microarray elements). AIPC
samples showed strong UBE2C staining, whereas weak and
no staining was observed in ADPC and normal prostate, respec-
tively (Figures 6A and 6B). These data suggest that UBE2C
protein overexpression correlates with the occurrence and
progression of prostate cancer.
To investigate whether the overexpression of UBE2C protein
in clinical samples is also caused by enhanced AR transcription
complex occupancy at the UBE2C enhancers, we performed
AR, FoxA1, H3K4me1 and H3K4me2 ChIP using tissues from
ADPC and AIPC cases. We found significantly greater AR and
FoxA1 occupancy and H3K4 methylation at the UBE2C en-
hancers in a case of AIPC as compared with an ADPC case
(Figure S14). While limited by the number of available cases for
analysis, this finding is consistent with our findings in LNCaP
and abl and supports the conclusion that increased H3K4 meth-
ylation and FoxA1 and AR occupancy at the UBE2C enhancers
leads to increased UBE2C expression in AIPC.
Functional Role of UBE2C in AIPC Growth
Finally, we explored the functional role of UBE2C in prostate
cancer growth. Although overexpression of UBE2C in LNCaP
cells is not sufficient to accelerate LNCaP cell grow in the
absence of androgen (Figure S15), silencing of UBE2C selec-
tively decreases abl (two-side t test, p = 9.1 3 103) but not
LNCaP cell proliferation (Figure 7A), suggesting that UBE2C is
necessary for abl cell proliferation in the absence of hormone
(Figures 7A and S1A). The UBE2C protein half-life of 6 hr in
both LNCaP and abl cells (Figure S16) suggests that it is AR-
dependent androgen-independent upregulation UBE2C tran-
scription (Figures 4–6 and S14) rather than a more stable
UBE2C protein that contributes to its increased level and the
increased growth of abl cells in the absence of androgen.
Consistent with the critical role of UBE2C in inactivating the
M-phase checkpoint (Reddy et al., 2007), fluorescence-activated
cell sorting (FACS) analysis revealed that silencing of UBE2C
causes a G2/M accumulation in both cell lines (Figure 7B). As
previously reported, AR silencing leads to a G1/S block in LNCaP
cells (Comstock and Knudsen, 2007), however it leads to a G2/M
block in abl cells (Figure 7B). This increase in G2/M phase cells
was further confirmed by an increase in histone H3 serine 10
phosphorylation (P-H3Ser10) level (Figure 7C) that peaks in
metaphase (Prigent and Dimitrov, 2003). Interestingly, silencing
of UBE2C in both LNCaP and abl cells also led to an increase
S phase (Figure 7B), which could caused by either a S phase
block or a shortened G1. To distinguish between these twoCell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc. 251
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Figure 5. H3K4me2 and FoxA1 Act Upstream of AR and Are Required for Differential AR Binding in abl Cells
(A) Overexpression of KDM1 abolishes differential AR binding in LNCaP and abl cells. Cells were transfected with a FLAG-tagged KDM1 vector or an empty vector
control. Three days after transfection, cells were treated with (+) or without (-) DHT. AR ChIP was then performed on the UBE2C enhancers. The overexpression of
KDM1 levels was monitored by western blot.
(B) FoxA1 silencing abolishes differential AR binding in LNCaP and abl cells. Cells were transfected with siFoxA1. AR ChIP was then performed in the presence (+)
and absence () of DHT on the UBE2C enhancers. The reduction of FoxA1 protein level was verified by western blot.
(C) AR silencing has no effect on differential H3K4me2 level and FoxA1 recruitment. Cells were transfected with siAR. H3K4me2 and FoxA1 ChIP were then
performed in the presence (+) and absence (-) of DHT on the UBE2C enhancers. The reduction of AR protein was demonstrated by western blot.
(D) A hierarchical model for AR action on the UBE2C enhancers. H3K4 methylation and FoxA1 act upstream of AR, and H3K4 methylation functions upstream of
FoxA1.252 Cell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc.
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Figure 6. UBE2C Protein Expression Level
Is Overexpressed in AIPC Cases
(A) Representative tissue microarray elements
stained with an antibody against UBE2C (magnifi-
cation 203). Stronger staining of UBE2C was seen
in AIPC than in ADPC.
(B) Analysis of UBE2C protein expression in
normal prostate, ADPC and AIPC. Tissue microar-
rays were scanned and scored using the Ariol
image analysis system. Nuclear staining and total
staining reflect a combination of the percentage
of positive nuclei and the intensity of the stain,
and a combination of the positive area score and
the intensity of the stain, respectively. AIPC has
stronger nuclear staining and total staining than
ADPC (Welch one-side t test, p < 2.2 3 1016 for
both staining scores). ADPC has higher nuclear
staining and total staining scores compared with
normal prostate (p = 5.80 3 1013, p < 2.2 3
1016, respectively).possibilities, we synchronized siControl and siUBE2C trans-
fected LNCaP and abl cells in G0 by serum starvation. Cells
were then released into cell cycle by the addition of serum. We
measured cyclin A protein level over time as this cyclin is not de-
tected during early G1, accumulates at the end of G1 and is
essential for G1/S transition (Girard et al., 1991; Resnitzky et al.,
1995). Interestingly, we found that Cyclin A accumulated 2 hr
earlier in siUBE2C transfected (12 hr) than in siControl transfected
(14 hr) LNCaP cells (Figure 7D). In contrast, Cyclin A was detected
at the same time point (14 hr) in siUBE2C and siControl trans-
fected abl cells (Figure 7D). These data suggest that UBE2C
silencing results in a shortened G1 phase in LNCaP but not in
abl cells. Thus the increased S phase fraction observed upon
UBE2C silencing (Figure 6B) is likely a result of a delayed S phase
in abl cells and shortened G1 phase in LNCaP cells. This may
explain why silencing of UBE2C decreases abl but not LNCaP
proliferation, even though UBE2C silencing results in G2/M block
in both cell lines. The more significant effect CDK1 and CDC20
silencing on cell proliferation in abl cells than in LNCaP cells
(Figure S17) may also be the result of a similar mechanism.
DISCUSSION
AR has been found to play a critical role in the development of
both ADPC and most cases of AIPC (Debes and Tindall, 2004;
Feldman and Feldman, 2001; Heinlein and Chang, 2004). In
ADPC, AR promotes cell proliferation through regulation of the
cell cycle G1/S transition only in the presence of androgen (Com-
stock and Knudsen, 2007). In contrast, in AIPC, AR is thought to
remain active through a variety of potential mechanisms in-
cluding AR amplification, AR mutation, increased androgen
sensitivity, local androgen production and growth factor activa-
tion (Debes and Tindall, 2004; Feldman and Feldman, 2001;
Heinlein and Chang, 2004). However, which of these mecha-
nisms is operant and how the ‘‘activated’’ AR regulates AIPCgrowth is poorly understood. In this study, using cell line models
of AIPC and gene expression data and tissue from actual AIPC
cases, we find that the program of gene expression regulated
by AR in the absence of hormone is distinct from the
androgen-regulated program in ADPC.
In contrast to a differentiated prostate program regulated by
androgens in LNCaP, AR regulates mitotic cell-cycle genes in
abl raising the question as to how this different AR-dependent
program is executed in abl cells. Through an integrated analysis
of AR cistrome and gene expression data, we found that upregu-
lated genes including cell-cycle genes in abl cells are direct AR
direct targets (Figure 2B). By analyzing the epigenetic marks
and collaborating transcription factors present at the AR bound
M-phase gene enhancers we explored the mechanisms under-
lying the reprogrammed AR action in both a AIPC model system
and clinical cases of AIPC. We found levels of active H3K4
methyl marks and recruitment of other transcription factors
including FoxA1 at AR target enhancers, most notably the
UBE2C enhancers. Although increased H3K4 methylation may
lead to increased recruitment of FoxA1 to facilitate greater AR
occupancy (Figures S8 and 5), these active histone marks may
also act upstream of other transcription factors and coactivators
(e.g., GATA2 and MED1) or directly on AR resulting in increased
AR binding at these sites in AIPC. It is also possible that other
active histone marks present on gene enhancers (Barski et al.,
2007) may play a role to facilitate transcription factor and coac-
tivator recruitment. Interestingly, while silencing of FoxA1 does
not affect AR target genes PSA and TMPRSS2 expression and
androgen-induced cell-cycle progression in LNCaP cells
(Wang et al., 2007), FoxA1 function is required for UBE2C
expression in abl cells, suggesting that FoxA1 may play a more
important role in AIPC than in ADPC.
The finding that differential H3K4 marks are required for differ-
ential AR binding raises the question of what are the mechanisms
responsible for the establishment of the differential histone marksCell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc. 253
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Figure 7. UBE2C Silencing Selectively Decreases abl Cell Growth
(A) Silencing of UBE2C selectively decreases abl cell proliferation. LNCaP and abl were plated as described in Figure 1.The cell proliferation was measured on
day 2 and day 4 after siRNA transfection using the WST-1 assay (mean [n = 3] ± SE).
(B) Silencing of UBE2C increases G2/M and S phase cells in LNCaP and abl cells. Ninety-six hr after siRNAs transfection in the absence of DHT, cells were
analyzed by FACS (mean [n = 2] ± SE).
(C) Silencing of UBE2C leads to a prolonged mitosis as indicated by P-H3Ser10. Ninety-six hr post siRNAs transfection in the absence of DHT, western blots were
performed with histone extraction (for P-H3Ser10 and total H3) or whole-cell lysate (for UBE2C and calnexin) using the antibodies indicated.
(D) UBE2C silencing results in a shortened G1 in LNCaP cells but not in abl cells. LNCaP and abl cells were transfected with siControl or siUBE2C in the absence of
DHT. After 6–8 hr, cells were synchronized in G0 by serum starvation for 24 hr. Cells were stimulated to re-enter cell cycle by the addition of 20% serum and
harvested at the indicated time points. Cell lysates were subjected to western blot with the indicated antibodies.in AIPC versus ADPC. It is possible that the expression of H3K4
histone methyltransferases is higher in AIPC than in ADPC. Alter-
natively, it is conceivable that the specific mechanisms for re-
cruiting the enzymes that make these marks exist in AIPC but
not in ADPC (Kouzarides, 2007; Ruthenburg et al., 2007). Future
studies will be needed to address these possibilities.
Our findings that AR selectively and directly upregulates
M-phase genes in AIPC may explain why maximal androgen
blockade that combines AR antagonists with LHRH inhibitors
cannot prolong AIPC patient survival (Group, 2000) as such
therapies will only inhibit the ability of androgen-bound AR to
promote G1/S transition in ADPC but cannot prevent un-li-
ganded AR from accelerating M-phase transition in AIPC. Inter-
estingly, two recent clinical trials have shown that docetaxel,
which disrupts mitosis by inhibiting the depolymerization of
microtubules, can modestly improve survival of AIPC patients
(Petrylak et al., 2004; Tannock et al., 2004), supporting an impor-
tant role of M-phase in AIPC progression.254 Cell 138, 245–256, July 24, 2009 ª2009 Elsevier Inc.Among the M-phase regulatory genes controlled by AR in AIPC
we find that UBE2C protein is overexpressed in AIPC cases. Inter-
estingly, UBE2C has also been found to be overexpressed in
breast, lung, ovary, bladder, thyroid and esophageal carcinomas
(Lin et al., 2006; Pallante et al., 2005; Wagner et al., 2004), sug-
gesting a general role of UBE2C in accelerating M-phase transi-
tion in solid tumors. Importantly, silencing of UBE2C significantly
decreases AIPC growth by arresting G2/M and S phases,
providing a potential new target for therapeutic intervention.
EXPERIMENTAL PROCEDURES
Cell Lines and Samples
The prostate cancer cell line LNCaP was obtained from the American Type
Culture Collection. abl cell line was provided by Zoran Culig (Innsbruck
Medical University, Austria) (Culig et al., 1999). C4-2B cell line was obtained
from ViroMed Laboratories (Minneapolis, MN). The prostate cancer tissue mi-
croarrays that include 44 normal prostate specimens, 98 ADPC specimens,
and 230 AIPC specimens were obtained from Arul Chinnaiyan (University of
Michigan, MI) and Mark Rubin (Cornell University, NY) as previously described
(Rubin et al., 2002). One ADPC tissue and one AIPC tissue used for tissue ChIP
were obtained form Arul Chinnaiyan.
Cell Proliferation Assay
Cell proliferation was determined using a WST-1 kit (Roche, Indianapolis, IN).
RNA Interference
A control siRNA (siControl) and siRNA targeting AR, CDC20, UBE2C, and
CDK1 (ON TARGET plus siRNA) were purchased from Dharmacon (Dharma-
con, Lafayette, CO). A second siAR has been described (Haag et al., 2005).
siRNA transfections were performed using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). The siRNA sequences were listed in Table S1.
Gene Expression Experiments and Analyses
Hormone-depleted LNCaP and abl cells were transfected with siControl or
siAR and abl cells were treated with 100 nM DHT or vehicle. Seventy-two hours
after siRNA transfection or four and sixteen hours after DHT treatment, total
RNA was isolated using an RNeasy kit (QIAGEN, Valencia, CA). Biological trip-
licate total RNA was hybridized to Affymetrix human U133 plus 2.0 expression
array (Affymetrix, Santa Clara, CA) at the Dana-Farber Cancer Institute (DFCI)
Microarray Core Facility. Microarray data have been submitted to the Gene
Expression Omnibus (GEO) repository under the accession number
GSE11428. The expression raw data for LNCaP cells in the presence or
absence of androgen was from our previous work (Wang et al., 2007) (GEO da-
taset GSE7868). Two clinical ADPC/AIPC expression data were retrieved from
GSE3325 and obtained from Steve Balk. All gene expression data was normal-
ized and summarized with RMA algorithm (Irizarry et al., 2003) and an updated
RefSeq probe definition (Dai et al., 2005). Significance Analysis of Microarrays
(SAM) algorithm (Tusher et al., 2001) was used to detect the differentially ex-
pressed genes and calculate the q-values (False Discovery Rate). Genes with
q-value less than 0.05 was used to select the differentially expressed genes.
Two-way hierarchical clustering analysis was performed to group both gene
expression changes (rows) and conditions (columns). Gene Ontology (GO)
analysis was performed using the web tool Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/).
ChIP-on-Chip and Standard ChIP Assays
AR ChIP was performed as previously described (Wang et al., 2007). The ChIP-
enriched DNA was amplified, labeled, and hybridized to Affymetrix Human
Tiling 2.0R Array Set. Biological triplicate experiments were performed. The
ChIP-on-chip raw data are accessible at http://research.dfci.harvard.edu/
brownlab/datasets/. ChIP-on-chip data were analyzed using MAT algorithm
(Johnson et al., 2006). Antibodies used for ChIP are available in the Supple-
mental Experimental Procedures.
Correlation of AR Binding to Gene Expression
Genes having AR binding sites within certain distance were defined as those
having at least one such site within the distance relative to the transcription start
sites. For each category of AR-regulated genes, the percentage of genes having
AR binding sites in LNCaP or abl cells within 20–100 kb was calculated. All
RefSeq genes in Affymetrix human U133 plus 2.0 expression array were used
as the control category. Chi-square test was used to assess the statistical
significance for the percentages of AR-regulated genes having AR binding sites.
Real-Time RT-PCR
Real-time RT-PCR was performed as before (Wang et al., 2007). Primers used
are listed in Table S1.
Western Blots
Western blots were performed as previously described (Wang et al., 2002).
Antibodies used are available in the Supplemental Experimental Procedures.
Quantitative Chromosome Conformation Capture Assay
3C-qPCR assays were performed essentially as described (Hagege et al.,
2007) with minor modifications. Details are available in the Supplemental
Experimental Procedures.Tissue Microarray Analysis
The immunohistochemistry of UBE2C on tissue microarrays was performed as
described (Wang et al., 2008) using anti-UBE2C (A650) at 1:600 dilution.
Details are available in the Supplemental Experimental Procedures.
Fluorescence-Activated Cell Sorting Analysis
siRNA transfected LNCaP and abl cells were collected, stained with propidium
iodide and DNA contents were analyzed by DFCI Cytometry Core Facility.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, seventeen figures, and two tables and can be found with
this article online at http://www.cell.com/supplemental/S0092-8674(09)00517-0.
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